2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 343

Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
Abstract Number: 344

Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Abstract Number: 345

Snap Crackle Pop: Healing the Cracks in Our Referral Process, Helping Pediatric Rheumatology Patients Get Care Sooner
Abstract Number: 346

Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Abstract Number: 347

Effectiveness of a Biopsychosocial Exercise Approach in Rheumatic Diseases
Abstract Number: 348

Psychometric Validation of the Arthritis Helplessness Index in Systemic Lupus Erythematosus
Abstract Number: 349

Improving the Performance of the Spanish Version of QOL-RA
Abstract Number: 350

Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
Abstract Number: 351

Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
Abstract Number: 352

Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
Abstract Number: 353

Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years
Abstract Number: 354

Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
Abstract Number: 355

Association of HLA-DRB1 Shared Epitope Alleles with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Abstract Number: 356

Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill
Abstract Number: 357

Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].